Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that finasteride treatment in men with androgenetic alopecia appears to restore caspase and XIAP expression in hair follicles to levels similar to those in individuals without the condition.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.

This study found that finasteride impaired stress reactivity and reduced exploratory and impulsive behaviors in rats, potentially by altering the hypothalamus-pituitary-adrenal axis function.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

In this laboratory study with rats, treatment with finasteride reduced dihydrotestosterone levels and fertility parameters, with a 30-day recovery period proving insufficient to fully restore sperm function and fertility.

This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.

In this study, treatment with finasteride 1 mg/day for five years significantly reduced the likelihood of further visible hair loss in men with androgenetic alopecia compared to placebo.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This study found that long-term treatment with finasteride 1 mg/day significantly improved scalp hair growth and was well tolerated in men with androgenetic alopecia over five years compared to placebo.

Accurate method measures finasteride levels in human plasma using gas chromatography-mass spectrometry.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.

This study found that repeated finasteride administration in male Wistar rats led to increased depression-like behavior, suggesting an animal model for investigating finasteride's neuropsychiatric effects is viable.

This study reports that finasteride was associated with an improvement in hidradenitis suppurativa among children aged 6 to 11, with no observed adverse effects.

Combining platelet-rich plasma with 5% minoxidil solution improves hair regrowth in androgenetic alopecia patients.

This study found that the risk of persistent sexual dysfunction was higher in men who stopped using finasteride 1 mg compared to omeprazole users.

In this study, researchers observed that the sexual effects of dihydrotestosterone deprivation using finasteride may vary by handedness, with right-handed men often experiencing lower sexual function and left-handed men showing no effect or improvement.

This study found that the solubilities of flutamide, dutasteride, and finasteride in supercritical carbon dioxide were effectively modeled using semiempirical equations by Chrastil and Bartle, with varying levels of accuracy.

This study determined that previous reports mistakenly identified different polymorphs of furosemide and finasteride, which are actually identical, due to incomplete data collection in single-crystal X-ray diffraction analysis.

Finasteride slows down motherly behavior in first-time pregnant rats.

This study developed and validated a high-performance liquid chromatographic method for identifying finasteride and its degradation products, showing excellent resolution and sensitivity under various decomposition conditions.

This study developed and validated an HPLC method for detecting a novel 5α-reductase inhibitor in human plasma, supporting its pharmacokinetic evaluation at low doses.

This study found that finasteride microemulsions significantly increased skin permeability in vitro, highlighting the potential for enhanced delivery of this drug through the skin.

This study found that finasteride use was not associated with sexual dysfunction in men with androgenetic alopecia, consistent with other large survey-based controlled studies.

The study found that finasteride increased endoplasmic reticulum stress and reduced fertility in rats, effects that were alleviated by the administration of DA-9401.

This study found that a new hybrid compound designed from finasteride and epristeride was a potent inhibitor of 5α-reductase with a mechanism similar to finasteride.

This study describes a validated UPLC-MS/MS method for quantifying finasteride in human plasma, demonstrating higher specificity, improved resolution, increased sensitivity, and faster analysis times compared to conventional HPLC-MS/MS methods.

This study identified previously unknown phase I and phase II metabolites of finasteride in human bile and urine using a specialized bile collection technique and advanced mass spectrometry analysis.

This study found that exposure to finasteride impaired spermatogenesis in male Xenopus laevis by affecting sex-specific feedback mechanisms in the hypothalamus–pituitary–gonad axis.